Company
Neurocrine Biosciences
Neurocrine Biosciences has 26 drugs tracked on RxWires: 1 post-market, 7 in Phase 3, 10 in Phase 2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Valbenazine | Post-Market | Schizophrenia |
| Osavampator | Phase 3 | Major Depressive Disorder |
| NBI-34060 | Phase 3 | Insomnia |
| NBI-1065845 | Phase 3 | Major Depressive Disorder |
| NBI-1117568 | Phase 3 | Schizophrenia |
| NBI-98854 | Phase 3 | Tardive Dyskinesia |
| Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia |
| Indiplon | Phase 3 | Insomnia |
| NBI-1070770 | Phase 2 | Major Depressive Disorder |
| Luvadaxistat | Phase 2 | Schizophrenia |
| NBI-921352 | Phase 2 | Focal Onset Seizure |
| NBI-1117570 | Phase 2 | Schizophrenia |
| NBI-74788 | Phase 2 | CAH - Congenital Adrenal Hyperplasia |
| interleukin-4 PE38KDEL cytotoxin | Phase 2 | Brain and Central Nervous System Tumors |
| TAK-831 | Phase 2 | Friedreich Ataxia |
| NBIP-01435 | Phase 2 | Congenital Adrenal Hyperplasia |
| NBI-1117567 | Phase 2 | Alzheimer's Disease |
| NBI-1065890 | Phase 2 | Tardive Dyskinesia |
| NBI-77860 | Phase 1 | Congenital Adrenal Hyperplasia |
| NBI-6024 | Phase 1 | Type 1 Diabetes Mellitus |
| TAK-653 | Phase 1 | Depressive Disorder |
| VY-AADC01 | Phase 1 | Parkinson's Disease |
| TAK-831 T2 | Phase 1 | Healthy Volunteers |
| TAK-041 | Phase 1 | Healthy Volunteers |
| VY-AADC02 | Phase 1 | Parkinson's Disease |
| NBI-98854 50 mg capsule once daily | Phase 1 | Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects |
Latest
- neurocrine biosciences filed 8-K
- neurocrine biosciences filed 8-K
- neurocrine biosciences filed 8-K
- neurocrine biosciences filed 8-K
- Merger or Acquisition: neurocrine biosciences
Follow Neurocrine Biosciences on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.